A study conducted in adults and children (4 to 65 years) with idiopathic generalised epilepsy with primary generalised tonic-clonic seizures showed that 39.2% of the patients in the Keppra group and 29.8% of the patients in the placebo group experienced undesirable effects that were judged to be related to treatment.